Shockwave Medical (BOVESPA:S2WA34) - Aandelenkoers, Nieuws & Analyse

S2WA34 Overzicht aandelen

A medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally.

Over het bedrijf

S2WA34 fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	3/6
Prestaties in het verleden	3/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

De winst zal naar verwachting met 18.35% per jaar groeien

Risicoanalyse

Aandelen zijn zeer illiquide

Aandeelhouders zijn het afgelopen jaar verwaterd

Winstmarges (20.7%) zijn lager dan vorig jaar (43.2%)

Shockwave Medical, Inc. Concurrenten

Rede D'Or São Luiz

BOVESPA:RDOR3

R$65.3b

Cochlear

ASX:COH

AU$18.6b

Insulet

NasdaqGS:PODD

US$16.4b

Sysmex

TSE:6869

JP¥1.8t

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Shockwave Medical
Historische aandelenkoersen
Huidige aandelenkoers	US$97.24
52 Week Hoogtepunt	US$97.24
52 Week Laag	US$46.75
Bèta	0.88
11 maand verandering	2.36%
3 maanden verandering	n/a
1 Jaar Verandering	19.87%
33 jaar verandering	n/a
5 jaar verandering	n/a
Verandering sinds IPO	129.31%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	S2WA34	BR Medical Equipment	BR Markt
7D	1.3%	-1.0%	-0.2%
1Y	19.9%	26.2%	10.2%

Rendement versus industrie: S2WA34 overtrof de BR Medical Equipment industrie, die het afgelopen jaar een rendement 19.7 % opleverde.

Rendement versus markt: S2WA34 overtrof de BR markt, die het afgelopen jaar een rendement opleverde van 10.4 %.

Prijsvolatiliteit

Is S2WA34's price volatile compared to industry and market?
S2WA34 volatility
S2WA34 Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	7.3%
Market Average Movement	4.4%
10% most volatile stocks in BR Market	8.9%
10% least volatile stocks in BR Market	2.3%

Stabiele aandelenkoers: S2WA34 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van S2WA34 in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2009	1,468	Doug Godshall	shockwavemedical.com

Shockwave Medical, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Shockwave Medical zich tot de beurswaarde?
S2WA34 fundamentele statistieken
Marktkapitalisatie	R$65.47b
Inkomsten(TTM)	R$851.49m
Inkomsten(TTM)	R$4.10b

76.9x

Koers/Winstverhouding

15.9x

P/S-verhouding

Is S2WA34 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
S2WA34 resultatenrekening (TTM)
Inkomsten	US$787.97m
Kosten van inkomsten	US$102.53m
Brutowinst	US$685.44m
Overige uitgaven	US$521.94m
Inkomsten	US$163.50m

Laatst gerapporteerde inkomsten

Mar 31, 2024

Volgende inkomensdatum

Aug 05, 2024

Winst per aandeel (EPS)	4.35
Brutomarge	86.99%
Nettowinstmarge	20.75%
Schuld/Eigen Vermogen Verhouding	97.5%

Hoe presteerde S2WA34 op de lange termijn?

Bekijk historische prestaties en vergelijking

S2WA34 Overzicht aandelen

Beloningen

Risicoanalyse

Shockwave Medical, Inc. Concurrenten

BOVESPA:RDOR3

R$65.3b

ASX:COH

AU$18.6b

NasdaqGS:PODD

US$16.4b

TSE:6869

JP¥1.8t

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Shockwave Medical, Inc. Announces U.S. Launch of the Shockwave E8 Peripheral Ivl Catheter

Shockwave Medical Files Form 15

Shockwave's Common Stock Ceases Trading on NASDAQ

Shockwave Medical, Inc. Announces Termination of Employment of Renee Gaeta as Chief Financial Officer

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Shockwave Medical, Inc. (NasdaqGS:SWAV) from a group of sellers.

Shockwave Medical Withdraws Earnings Guidance for the Full Year 2024

Recent updates

Shockwave Medical, Inc. Announces U.S. Launch of the Shockwave E8 Peripheral Ivl Catheter

Shockwave Medical Files Form 15

Shockwave's Common Stock Ceases Trading on NASDAQ

Shockwave Medical, Inc. Announces Termination of Employment of Renee Gaeta as Chief Financial Officer

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Shockwave Medical, Inc. (NasdaqGS:SWAV) from a group of sellers.

Shockwave Medical Withdraws Earnings Guidance for the Full Year 2024

Shockwave Medical, Inc., Annual General Meeting, May 29, 2024

Shockwave Medical, Inc. Announces Investigators Presented Six-Month Data from the Full Population of the Reducer-I Study

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Shockwave Medical, Inc. (NasdaqGS:SWAV) for $13 billion.

Johnson & Johnson Reportedly Considers Deal for Shockwave Medical

Shockwave Medical, Inc. Provides Earnings Guidance for 2024

Shockwave Medical, Inc. Appoints Renee Gaeta as Chief Financial Officer, Effective February 5, 2024

Shockwave Medical, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Shockwave Medical, Inc. Announces New Data Demonstrating One-Year Outcomes with Coronary Lithotripsy

Shockwave Medical, Inc. Provides Revenue Guidance for the Full Year 2023

Shockwave Medical, Inc. Introduces Enhanced Coronary IVL Catheter in the United States

Shockwave Medical, Inc. Announces New Shockwave Coronary IVL Publications Confirm Safety and Efficacy Across Multiple Calcium Morphologies

Shockwave Medical, Inc. Appoints Nick West as Associate Chief Medical Officer

Daniel K. Puckett Notifies Shockwave Medical, Inc. of His Intention to Retire as Chief Financial Officer

Daniel K. Puckett Notifies Shockwave Medical, Inc. of His Intention to Retire as Chief Financial Officer

Shockwave Medical, Inc. Revises Revenue Guidance for the Full Year 2023

Shockwave Medical, Inc.(NasdaqGS:SWAV) dropped from Russell 2000 Dynamic Index

Shockwave Medical, Inc. Appoints Kevin Ballinger to Board of Directors and Will Serve on Shockwave’s Nominating and ESG Committee and the Compensation Committee of the Board

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Shockwave Medical, Inc. Revises Revenue Guidance for the Year 2023

Shockwave Medical, Inc. Provides Earnings Guidance for the Full Year 2023

ShockWave Medical, Inc. (NasdaqGS:SWAV) entered into a definitive agreement to acquire Neovasc Inc. (TSX:NVCN) from Strul Medical Group LLC and others for $75.04 million.

ShockWave Medical, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2022 and Fiscal Year 2023

ShockWave Medical, Inc. to Report Q4, 2022 Results on Feb 16, 2023

ShockWave Medical, Inc. Revises Revenue Guidance for the Year 2022

ShockWave Medical, Inc. Confirms Consistent Outcomes for IVL in the larger Prospective “Real World” Study of Patients with Heavily Calcified Peripheral Arterial Disease

ShockWave Medical, Inc. Revises Revenue Guidance for the Full Year 2022

Shockwave Medical, Inc. and Genesis MedTech Group Successfully Obtains Approval from China’S National Medical Products Administration to Market and Sell the Shockwave IVL System with the Shockwave C2 Coronary IVL Catheters and the Shockwave M5 and S4 Peripheral IVL Catheters in China

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Shockwave Medical, Inc. Samenvatting

76.9x

15.9x

Inkomsten en omzet